NellOne Therapeutics
NellOne is an early stage biopharmaceutical company pioneering advances in regenerative medicine. Its mission is to relieve suffering and restore lives by returning damaged soft and hard tissue to its pre-injury state, utilizing the NELL1 protein to promote tissue regeneration, control inflammation, and improve patient outcomes. The company is dedicated to harnessing the power of the NELL1 / NV1 protein to improve outcomes for patients worldwide suffering from significant soft tissue damage due to traumatic injuries or diseases. NellOne is also actively involved in research supported by the National Science Foundation to evaluate the therapeutic potential of NV1, a proprietary variant of NELL1, for treating lung tissue damage such as that caused by severe viral infections like COVID-19 and flu.
Industries
Nr. of Employees
small (1-50)
NellOne Therapeutics
Products
Engineered recombinant signaling protein therapeutic candidate
A shortened, engineered recombinant variant of a developmental matricellular signaling protein developed to reduce inflammation and promote regeneration of soft and hard tissues; described as having improved functional effects and higher production yields versus the native protein. Preclinical work includes cultured human lung tissue studies and pilot SARS‑CoV‑2 mouse studies assessing survival and lung repair.
Engineered recombinant signaling protein therapeutic candidate
A shortened, engineered recombinant variant of a developmental matricellular signaling protein developed to reduce inflammation and promote regeneration of soft and hard tissues; described as having improved functional effects and higher production yields versus the native protein. Preclinical work includes cultured human lung tissue studies and pilot SARS‑CoV‑2 mouse studies assessing survival and lung repair.
Services
Technology licensing and collaborative R&D partnerships
License inbound technologies and form collaborative research partnerships with national laboratories, contract developers, and assay providers to accelerate development and access specialized platforms.
Preclinical study collaboration and assay development
Collaborative development of preclinical studies and specialized assays to evaluate efficacy, optimize formulations, and support regulatory filings.
Government grant-supported preclinical R&D
Management and execution of SBIR-funded preclinical research programs, including evaluation in cultured human tissues and animal infection models to generate translational data for regulatory and development milestones.
Technology licensing and collaborative R&D partnerships
License inbound technologies and form collaborative research partnerships with national laboratories, contract developers, and assay providers to accelerate development and access specialized platforms.
Preclinical study collaboration and assay development
Collaborative development of preclinical studies and specialized assays to evaluate efficacy, optimize formulations, and support regulatory filings.
Government grant-supported preclinical R&D
Management and execution of SBIR-funded preclinical research programs, including evaluation in cultured human tissues and animal infection models to generate translational data for regulatory and development milestones.
Expertise Areas
- Regenerative medicine and tissue engineering
- Recombinant protein therapeutic development
- Preclinical translational development for respiratory and musculoskeletal injuries
- Nanoparticle and targeted drug delivery research
Key Technologies
- Recombinant protein therapeutics
- Protein engineering for improved yield and manufacturability
- Organotypic cultured human lung tissue models
- In vivo viral infection animal models (SARS‑CoV‑2 mouse models)